Published in Cancer Microenviron on August 03, 2011
Heparanase regulates secretion, composition, and function of tumor cell-derived exosomes. J Biol Chem (2013) 1.49
Heparan sulfate and heparanase play key roles in mouse β cell survival and autoimmune diabetes. J Clin Invest (2011) 1.47
Model of fibrolamellar hepatocellular carcinomas reveals striking enrichment in cancer stem cells. Nat Commun (2015) 1.43
The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer (2015) 1.43
The Role of Heparanase and Sulfatases in the Modification of Heparan Sulfate Proteoglycans within the Tumor Microenvironment and Opportunities for Novel Cancer Therapeutics. Front Oncol (2014) 1.08
Heparanase cooperates with Ras to drive breast and skin tumorigenesis. Cancer Res (2014) 0.99
Proteoglycans and their roles in brain cancer. FEBS J (2013) 0.98
Glycosaminoglycan glycomics using mass spectrometry. Mol Cell Proteomics (2013) 0.94
Involvement of heparanase in atherosclerosis and other vessel wall pathologies. Matrix Biol (2013) 0.93
Holothurian glycosaminoglycan inhibits metastasis and thrombosis via targeting of nuclear factor-κB/tissue factor/Factor Xa pathway in melanoma B16F10 cells. PLoS One (2013) 0.89
Breast and ovarian cancers: a survey and possible roles for the cell surface heparan sulfate proteoglycans. J Histochem Cytochem (2012) 0.89
Invasion and metastasis of renal cell carcinoma. Med Mol Morphol (2013) 0.88
Processing of heparanase is mediated by syndecan-1 cytoplasmic domain and involves syntenin and α-actinin. Cell Mol Life Sci (2014) 0.87
Characterization of heparanase-induced phosphatidylinositol 3-kinase-AKT activation and its integrin dependence. J Biol Chem (2013) 0.86
Towards understanding the roles of heparan sulfate proteoglycans in Alzheimer's disease. Biomed Res Int (2014) 0.84
Heparan sulfate proteoglycans and human breast cancer epithelial cell tumorigenicity. J Cell Biochem (2014) 0.82
The Endothelial Glycocalyx: New Diagnostic and Therapeutic Approaches in Sepsis. Biomed Res Int (2016) 0.81
Heparanase-induced shedding of syndecan-1/CD138 in myeloma and endothelial cells activates VEGFR2 and an invasive phenotype: prevention by novel synstatins. Oncogenesis (2016) 0.81
Heparanase regulation of cancer, autophagy and inflammation: new mechanisms and targets for therapy. FEBS J (2016) 0.80
The role of heparanase in pulmonary cell recruitment in response to an allergic but not non-allergic stimulus. PLoS One (2015) 0.79
Heparanase is required for activation and function of macrophages. Proc Natl Acad Sci U S A (2016) 0.79
Heparanase 2 Attenuates Head and Neck Tumor Vascularity and Growth. Cancer Res (2016) 0.79
Heparan sulfate and heparanase as modulators of breast cancer progression. Biomed Res Int (2013) 0.79
Coexpression of heparanase activity, cathepsin L, tissue factor, tissue factor pathway inhibitor, and MMP-9 in proliferative diabetic retinopathy. Mol Vis (2016) 0.79
Cancer biology in diabetes. J Diabetes Investig (2014) 0.79
Expression of heparanase in soft tissue sarcomas of adults. J Exp Clin Cancer Res (2014) 0.79
Heparan sulfate differences in rheumatoid arthritis versus healthy sera. Matrix Biol (2014) 0.78
Heparanase expression upregulates platelet adhesion activity and thrombogenicity. Oncotarget (2016) 0.78
Heparanase interacts with resistin and augments its activity. PLoS One (2014) 0.77
Heparanase 2 expression inversely correlates with bladder carcinoma grade and stage. Oncotarget (2016) 0.77
Modification of heparanase gene expression in response to conditioning and LPS treatment: strong correlation to rs4693608 SNP. J Leukoc Biol (2013) 0.77
Development of novel single-stranded nucleic acid aptamers against the pro-angiogenic and metastatic enzyme heparanase (HPSE1). PLoS One (2012) 0.77
A liquid chromatography-mass spectrometry-based approach to characterize the substrate specificity of mammalian heparanase. J Biol Chem (2014) 0.77
The protective role of fucosylated chondroitin sulfate, a distinct glycosaminoglycan, in a murine model of streptozotocin-induced diabetic nephropathy. PLoS One (2014) 0.76
Combination therapy with low molecular weight heparin and Adriamycin results in decreased breast cancer cell metastasis in C3H mice. Exp Ther Med (2014) 0.76
Anti-heparanase aptamers as potential diagnostic and therapeutic agents for oral cancer. PLoS One (2014) 0.76
Involvement of Heparanase in Empyema: Implication for Novel Therapeutic Approaches. J Clin Cell Immunol (2015) 0.75
Heparanase promotes radiation resistance of cervical cancer by upregulating hypoxia inducible factor 1. Am J Cancer Res (2017) 0.75
Mechanisms of heparanase inhibitors in cancer therapy. Exp Hematol (2016) 0.75
Heparanase and cancer progression: New directions, new promises. Hum Vaccin Immunother (2016) 0.75
Overexpression of heparanase attenuated TGF-β-stimulated signaling in tumor cells. FEBS Open Bio (2017) 0.75
The prognostic significance of heparanase expression in metastatic melanoma. Oncotarget (2016) 0.75
Identification of Novel Class of Triazolo-Thiadiazoles as Potent Inhibitors of Human Heparanase and their Anticancer Activity. BMC Cancer (2017) 0.75
Involvement of heparanase in the pathogenesis of acute kidney injury: nephroprotective effect of PG545. Oncotarget (2017) 0.75
From gene discovery to new biological mechanisms: heparanases and congenital urinary bladder disease. Nephrol Dial Transplant (2015) 0.75
Tumor size, stage and grade alterations of urinary peptidome in RCC. J Transl Med (2015) 0.75
The Heparanase Inhibitor PG545 Attenuates Colon Cancer Initiation and Growth, Associating with Increased p21 Expression. Neoplasia (2017) 0.75
Heparanase Overexpression Reduces Hepcidin Expression, Affects Iron Homeostasis and Alters the Response to Inflammation. PLoS One (2016) 0.75
Lysosomal accumulation of anticancer drugs triggers lysosomal exocytosis. Oncotarget (2017) 0.75
The β-d-Endoglucuronidase Heparanase Is a Danger Molecule That Drives Systemic Inflammation and Correlates with Clinical Course after Open and Endovascular Thoracoabdominal Aortic Aneurysm Repair: Lessons Learnt from Mice and Men. Front Immunol (2017) 0.75
Elevated heparanase expression is associated with poor prognosis in breast cancer: a study based on systematic review and TCGA data. Oncotarget (2017) 0.75
Heparanase overexpression down-regulates syndecan-1 expression in a gallbladder carcinoma cell line. J Int Med Res (2017) 0.75
Intestinal anti-inflammatory activity of Ground Cherry (Physalis angulata L.) standardized CO2 phytopharmaceutical preparation. World J Gastroenterol (2017) 0.75
Immunity, inflammation, and cancer. Cell (2010) 28.27
Fibroblasts in cancer. Nat Rev Cancer (2006) 18.95
Nuclear factor-kappaB in cancer development and progression. Nature (2006) 18.31
IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell (2004) 15.82
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature (2005) 15.57
STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer (2009) 15.45
Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer (2004) 14.55
NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol (2005) 13.98
Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell (2006) 13.79
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med (2004) 13.34
Matrix metalloproteinases: regulators of the tumor microenvironment. Cell (2010) 12.90
Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science (2002) 12.29
Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem (1999) 11.87
Stromal fibroblasts in cancer initiation and progression. Nature (2004) 11.69
A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology (1990) 11.22
TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science (2004) 10.23
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov (2004) 9.96
The microenvironment of the tumour-host interface. Nature (2001) 9.17
The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol (2003) 8.28
Heparin-protein interactions. Angew Chem Int Ed Engl (2002) 7.27
Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol (2010) 6.85
Tumor self-seeding by circulating cancer cells. Cell (2009) 6.66
Proteoglycans: structures and interactions. Annu Rev Biochem (1991) 6.53
Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner. Cancer Cell (2010) 6.33
Experimental models of inflammatory bowel disease. Gastroenterology (1995) 6.28
Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest (2008) 5.26
Matrigel: basement membrane matrix with biological activity. Semin Cancer Biol (2005) 5.12
AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res (2010) 4.89
Matrix proteoglycans: from molecular design to cellular function. Annu Rev Biochem (1998) 4.86
Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology (2007) 3.99
Heparan sulphate proteoglycans: the sweet side of development. Nat Rev Mol Cell Biol (2005) 3.92
A heparin-binding angiogenic protein--basic fibroblast growth factor--is stored within basement membrane. Am J Pathol (1988) 3.72
Epidemiology of pancreatic cancer: an overview. Nat Rev Gastroenterol Hepatol (2009) 3.67
Interactions between heparan sulfate and proteins: the concept of specificity. J Cell Biol (2006) 3.49
Roles of heparan-sulphate glycosaminoglycans in cancer. Nat Rev Cancer (2002) 3.36
Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol (2006) 3.24
Supramolecular assembly of basement membranes. Bioessays (1996) 2.97
Preparing the "soil": the premetastatic niche. Cancer Res (2006) 2.92
Lysosomal cysteine proteases: more than scavengers. Biochim Biophys Acta (2000) 2.76
Heparanase: a key enzyme involved in cell invasion. Biochim Biophys Acta (2001) 2.74
Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis. J Natl Cancer Inst (2004) 2.52
Basic fibroblast growth factor binds to subendothelial extracellular matrix and is released by heparitinase and heparin-like molecules. Biochemistry (1989) 2.49
Radiation to stromal fibroblasts increases invasiveness of pancreatic cancer cells through tumor-stromal interactions. Cancer Res (2004) 2.42
Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. J Leukoc Biol (2006) 2.33
Role of cytokines in inflammatory bowel disease. World J Gastroenterol (2008) 2.30
Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma. Cancer Res (2001) 2.26
Carcinoma-associated fibroblasts are a rate-limiting determinant for tumour progression. Semin Cell Dev Biol (2009) 2.25
Cancer associated fibroblasts in cancer pathogenesis. Semin Cell Dev Biol (2009) 2.20
Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena. J Clin Invest (2001) 2.18
Heparan sulfate structure in mice with genetically modified heparan sulfate production. J Biol Chem (2004) 2.14
Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate. Curr Pharm Des (2007) 2.14
Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle (2007) 2.10
Proteolytic networks in cancer. Trends Cell Biol (2011) 2.10
Heparanase: busy at the cell surface. Trends Biochem Sci (2009) 2.07
Promotion of colorectal neoplasia in experimental murine ulcerative colitis. Gut (1996) 2.06
Lymphoma cell-mediated degradation of sulfated proteoglycans in the subendothelial extracellular matrix: relationship to tumor cell metastasis. Cancer Res (1983) 2.04
Heparanase as mediator of angiogenesis: mode of action. FASEB J (2001) 2.04
Bone marrow as a priming site for T-cell responses to blood-borne antigen. Nat Med (2003) 2.01
Integrins and angiogenesis. Curr Top Dev Biol (2004) 2.00
Morphological appearance, growth behavior and migratory activity of human tumor cells maintained on extracellular matrix versus plastic. Cell (1980) 1.94
Tissue architecture and function: dynamic reciprocity via extra- and intra-cellular matrices. Cancer Metastasis Rev (2009) 1.93
Mammalian heparanase: what is the message? J Cell Mol Med (2007) 1.91
Heparanase: a target for drug discovery in cancer and inflammation. Br J Pharmacol (2007) 1.90
Bone marrow cells in the 'pre-metastatic niche': within bone and beyond. Cancer Metastasis Rev (2006) 1.89
Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting. FEBS J (2010) 1.83
High heparanase activity in multiple myeloma is associated with elevated microvessel density. Cancer Res (2003) 1.81
Expression of heparanase by platelets and circulating cells of the immune system: possible involvement in diapedesis and extravasation. Invasion Metastasis (1992) 1.79
Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis. FEBS J (2010) 1.78
Involvement of heparan sulfate and related molecules in sequestration and growth promoting activity of fibroblast growth factor. Cancer Metastasis Rev (1996) 1.77
Organ specificity of tumor metastasis: role of preferential adhesion, invasion and growth of malignant cells at specific secondary sites. Cancer Metastasis Rev (1988) 1.75
Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma. J Biol Chem (2008) 1.74
Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J Clin Invest (2009) 1.73
Heparan sulfate proteoglycan as a plasma membrane carrier. Trends Biochem Sci (2003) 1.67
Interactions between heparan sulfate and proteins-design and functional implications. Int Rev Cell Mol Biol (2009) 1.67
Heparanase expression in primary and metastatic pancreatic cancer. Cancer Res (2001) 1.67
Extracellular matrix-resident growth factors and enzymes: possible involvement in tumor metastasis and angiogenesis. Cancer Metastasis Rev (1990) 1.66
The epidemiology of pancreatic cancer in the United States: changes below the surface. Aliment Pharmacol Ther (2006) 1.65
Transgenic expression of mammalian heparanase uncovers physiological functions of heparan sulfate in tissue morphogenesis, vascularization, and feeding behavior. FASEB J (2004) 1.64
Radiation therapy to a primary tumor accelerates metastatic growth in mice. Cancer Res (2001) 1.64
Heparan sulfate degradation: relation to tumor invasive and metastatic properties of mouse B16 melanoma sublines. Science (1983) 1.63
Respective roles of laminin and fibronectin in adhesion of human carcinoma and sarcoma cells. Nature (1981) 1.59
Cloning and expression profiling of Hpa2, a novel mammalian heparanase family member. Biochem Biophys Res Commun (2000) 1.59
Extracellular sequestration and release of fibroblast growth factor: a regulatory mechanism? Trends Biochem Sci (1991) 1.57
Tumor-microenvironment interactions: dangerous liaisons. Adv Cancer Res (2008) 1.56
Heparanase affects adhesive and tumorigenic potential of human glioma cells. Cancer Res (2003) 1.54
Matrix metalloproteinases at cancer tumor-host interface. Semin Cell Dev Biol (2007) 1.53
Innate immune signaling by Toll-like receptor-4 (TLR4) shapes the inflammatory microenvironment in colitis-associated tumors. Inflamm Bowel Dis (2009) 1.53
The key role of macrophages in the immunopathogenesis of inflammatory bowel disease. Inflamm Bowel Dis (2000) 1.53
Expression of heparanase in normal, dysplastic, and neoplastic human colonic mucosa and stroma. Evidence for its role in colonic tumorigenesis. Am J Pathol (2000) 1.52
Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting. J Biol Chem (2005) 1.52
Newly generated heparanase knock-out mice unravel co-regulation of heparanase and matrix metalloproteinases. PLoS One (2009) 1.46
The clinicopathological significance of heparanase and basic fibroblast growth factor expressions in hepatocellular carcinoma. Clin Cancer Res (2001) 1.44
A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282. Int J Radiat Oncol Biol Phys (2005) 1.43
Cathepsin L is responsible for processing and activation of proheparanase through multiple cleavages of a linker segment. J Biol Chem (2008) 1.43
A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer. Oncogene (2005) 1.43
Conditional signaling by Toll-like receptor 4. FASEB J (2005) 1.42
Heparanase promotes growth, angiogenesis and survival of primary breast tumors. Int J Cancer (2006) 1.42
Development of heparanase inhibitors for anti-cancer therapy. Curr Med Chem (2006) 1.41
Non-anticoagulant heparins and inhibition of cancer. Pathophysiol Haemost Thromb (2009) 1.41
Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol (2006) 3.24
Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis. J Natl Cancer Inst (2004) 2.52
Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate. Curr Pharm Des (2007) 2.14
Heparanase: busy at the cell surface. Trends Biochem Sci (2009) 2.07
Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation. Cancer Res (2006) 2.02
Processing and activation of latent heparanase occurs in lysosomes. J Cell Sci (2004) 1.82
Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis. FEBS J (2010) 1.78
Heparanase induces endothelial cell migration via protein kinase B/Akt activation. J Biol Chem (2004) 1.78
Transgenic expression of mammalian heparanase uncovers physiological functions of heparan sulfate in tissue morphogenesis, vascularization, and feeding behavior. FASEB J (2004) 1.64
Mammalian heparanase: involvement in cancer metastasis, angiogenesis and normal development. Semin Cancer Biol (2002) 1.57
Heparanase affects adhesive and tumorigenic potential of human glioma cells. Cancer Res (2003) 1.54
Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting. J Biol Chem (2005) 1.52
Heparanase uptake is mediated by cell membrane heparan sulfate proteoglycans. J Biol Chem (2004) 1.43
Heparanase promotes growth, angiogenesis and survival of primary breast tumors. Int J Cancer (2006) 1.42
Heparanase cleavage of perlecan heparan sulfate modulates FGF10 activity during ex vivo submandibular gland branching morphogenesis. Development (2007) 1.40
SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis. Clin Cancer Res (2011) 1.40
Development and therapeutic impact of HDAC6-selective inhibitors. Biochem Pharmacol (2012) 1.36
Heparanase augments epidermal growth factor receptor phosphorylation: correlation with head and neck tumor progression. Cancer Res (2008) 1.35
Role of endothelial heparanase in delayed-type hypersensitivity. Blood (2005) 1.35
Structure-function approach identifies a COOH-terminal domain that mediates heparanase signaling. Cancer Res (2009) 1.34
Heparanase accelerates wound angiogenesis and wound healing in mouse and rat models. FASEB J (2005) 1.32
Heparanase powers a chronic inflammatory circuit that promotes colitis-associated tumorigenesis in mice. J Clin Invest (2011) 1.32
Heparanase induces VEGF C and facilitates tumor lymphangiogenesis. Int J Cancer (2008) 1.31
Heparanase: one molecule with multiple functions in cancer progression. Connect Tissue Res (2008) 1.29
Heparanase is essential for the development of diabetic nephropathy in mice. Diabetes (2011) 1.29
The impact of heparanese and heparin on cancer metastasis and angiogenesis. Pathophysiol Haemost Thromb (2006) 1.29
Algorithmic guided screening of drug combinations of arbitrary size for activity against cancer cells. Mol Cancer Ther (2009) 1.28
The heparanase system and tumor metastasis: is heparanase the seed and soil? Cancer Metastasis Rev (2011) 1.28
Heparanase localization and expression by head and neck cancer: correlation with tumor progression and patient survival. Neoplasia (2006) 1.28
Identification and characterization of heparin/heparan sulfate binding domains of the endoglycosidase heparanase. J Biol Chem (2005) 1.27
Function of heparanase in prostate tumorigenesis: potential for therapy. Clin Cancer Res (2008) 1.25
Small cell (neuroendocrine) carcinoma of the prostate: etiology, diagnosis, prognosis, and therapeutic implications--a retrospective study of 30 patients from the rare cancer network. Am J Med Sci (2008) 1.23
Heparanase 2 interacts with heparan sulfate with high affinity and inhibits heparanase activity. J Biol Chem (2010) 1.19
Heterodimer formation is essential for heparanase enzymatic activity. Biochem Biophys Res Commun (2003) 1.17
Enzymatically quiescent heparanase augments T cell interactions with VCAM-1 and extracellular matrix components under versatile dynamic contexts. J Immunol (2004) 1.16
Heparanase-mediated loss of nuclear syndecan-1 enhances histone acetyltransferase (HAT) activity to promote expression of genes that drive an aggressive tumor phenotype. J Biol Chem (2011) 1.15
Heparanase facilitates cell adhesion and spreading by clustering of cell surface heparan sulfate proteoglycans. PLoS One (2008) 1.14
A novel human heparanase splice variant, T5, endowed with protumorigenic characteristics. FASEB J (2009) 1.13
Activation, processing and trafficking of extracellular heparanase by primary human fibroblasts. J Cell Sci (2002) 1.12
Thymosin beta4 increases hair growth by activation of hair follicle stem cells. FASEB J (2003) 1.10
Tumorigenic and adhesive properties of heparanase. Semin Cancer Biol (2010) 1.10
Heparanase upregulation by colonic epithelium in inflammatory bowel disease. Mod Pathol (2006) 1.09
Characterization of mechanisms involved in secretion of active heparanase. J Biol Chem (2006) 1.08
Human heparanase is localized within lysosomes in a stable form. Exp Cell Res (2002) 1.07
Heparanase levels are elevated in the plasma of pediatric cancer patients and correlate with response to anticancer treatment. Neoplasia (2007) 1.04
Synthesis and in vitro antitumor activity of new 4,5-dihydropyrazole derivatives. Bioorg Med Chem (2010) 1.04
Heparanase induces Akt phosphorylation via a lipid raft receptor. Biochem Biophys Res Commun (2007) 1.04
Triplex formation on DNA targets: how to choose the oligonucleotide. Biochemistry (2008) 1.03
An ELISA method for the detection and quantification of human heparanase. Biochem Biophys Res Commun (2006) 1.03
Alternatively spliced Spalax heparanase inhibits extracellular matrix degradation, tumor growth, and metastasis. Proc Natl Acad Sci U S A (2009) 1.02
Pre-clinical and clinical significance of heparanase in Ewing's sarcoma. J Cell Mol Med (2011) 1.02
Spatial and temporal heparanase expression in colon mucosa throughout the adenoma-carcinoma sequence. Mod Pathol (2006) 1.02
Heparanase levels are elevated in the urine and plasma of type 2 diabetes patients and associate with blood glucose levels. PLoS One (2011) 1.01
Clinical significance of urine heparanase in bladder cancer progression. Neoplasia (2008) 1.01
A placental growth factor variant unable to recognize vascular endothelial growth factor (VEGF) receptor-1 inhibits VEGF-dependent tumor angiogenesis via heterodimerization. Cancer Res (2010) 1.00
Human heparanase nuclear localization and enzymatic activity. Lab Invest (2004) 1.00
Role of heparanase in radiation-enhanced invasiveness of pancreatic carcinoma. Cancer Res (2011) 1.00
Propionyl-L-carnitine improves postischemic blood flow recovery and arteriogenetic revascularization and reduces endothelial NADPH-oxidase 4-mediated superoxide production. Arterioscler Thromb Vasc Biol (2010) 0.99
Undersulfated and glycol-split heparins endowed with antiangiogenic activity. J Med Chem (2004) 0.99
Identification of placenta growth factor determinants for binding and activation of Flt-1 receptor. J Biol Chem (2004) 0.99
Heparanase expression in malignant salivary gland tumors inversely correlates with long-term survival. Neoplasia (2006) 0.98
Macrophage activation by heparanase is mediated by TLR-2 and TLR-4 and associates with plaque progression. Arterioscler Thromb Vasc Biol (2012) 0.98
Heparanase induces signal transducer and activator of transcription (STAT) protein phosphorylation: preclinical and clinical significance in head and neck cancer. J Biol Chem (2011) 0.98
Heparanase regulates murine hair growth. Am J Pathol (2005) 0.97
Novel combretastatin analogues endowed with antitumor activity. J Med Chem (2006) 0.97
Short heparin sequences spaced by glycol-split uronate residues are antagonists of fibroblast growth factor 2 and angiogenesis inhibitors. Biochemistry (2002) 0.96
The enhancement of antiproliferative and proapoptotic activity of HDAC inhibitors by curcumin is mediated by Hsp90 inhibition. Cell Mol Life Sci (2009) 0.96
Heparanase induces tissue factor pathway inhibitor expression and extracellular accumulation in endothelial and tumor cells. Thromb Haemost (2008) 0.95
Novel camptothecin analogue (gimatecan)-containing liposomes prepared by the ethanol injection method. J Liposome Res (2004) 0.95
Acetyl-L-Carnitine prevents and reverts experimental chronic neurotoxicity induced by oxaliplatin, without altering its antitumor properties. Anticancer Res (2005) 0.95
Thymosin beta 4 induces hair growth via stem cell migration and differentiation. Ann N Y Acad Sci (2007) 0.95
Heparanase, heparin and the coagulation system in cancer progression. Thromb Res (2007) 0.95
Antiangiogenic effects of the novel camptothecin ST1481 (gimatecan) in human tumor xenografts. Mol Cancer Res (2003) 0.94
The identification of a novel natural activator of p300 histone acetyltranferase provides new insights into the modulation mechanism of this enzyme. Chembiochem (2010) 0.94
Biological and molecular properties of a new alpha(v)beta3/alpha(v)beta5 integrin antagonist. Mol Cancer Ther (2005) 0.93
The molecular and cellular basis of exostosis formation in hereditary multiple exostoses. Int J Exp Pathol (2008) 0.93
Involvement of heparanase in atherosclerosis and other vessel wall pathologies. Matrix Biol (2013) 0.93
Impact of heparanase and the tumor microenvironment on cancer metastasis and angiogenesis: basic aspects and clinical applications. Rambam Maimonides Med J (2011) 0.92
Post-transcriptional regulation of heparanase gene expression by a 3' AU-rich element. FASEB J (2010) 0.92
Heparanase processing by lysosomal/endosomal protein preparation. FEBS Lett (2005) 0.92
Heparanase is overexpressed in lung cancer and correlates inversely with patient survival. Cancer (2008) 0.92
Tamoxifen induces heparanase expression in estrogen receptor-positive breast cancer. Clin Cancer Res (2007) 0.92
Synthesis and structure-activity relationships of a new series of retinoid-related biphenyl-4-ylacrylic acids endowed with antiproliferative and proapoptotic activity. J Med Chem (2005) 0.92
Synthesis and biological activity of fluorinated combretastatin analogues. J Med Chem (2008) 0.92
Combretastatin CA-4 and combretastatin derivative induce mitotic catastrophe dependent on spindle checkpoint and caspase-3 activation in non-small cell lung cancer cells. Apoptosis (2007) 0.92
Low and high affinity receptors mediate cellular uptake of heparanase. Int J Biochem Cell Biol (2007) 0.91
Heparanase expression during normal liver development and following partial hepatectomy. J Pathol (2004) 0.91
Novel A-ring and B-ring modified combretastatin A-4 (CA-4) analogues endowed with interesting cytotoxic activity. J Med Chem (2008) 0.91
Heparanase up-regulation in tongue cancer: tissue and saliva analysis. Cancer (2007) 0.91
Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity. Cancer Res (2005) 0.90
A novel atypical retinoid endowed with proapoptotic and antitumor activity. J Med Chem (2003) 0.90
The curative efficacy of namitecan (ST1968) in preclinical models of pediatric sarcoma is associated with antiangiogenic effects. Biochem Pharmacol (2012) 0.90
Heparanase in inflammation and inflammation-associated cancer. FEBS J (2013) 0.90